Neurological manifestations of Behçet's disease: Evaluation of 40 patients treated by cyclophosphamide

Revue Neurologique

Volumn 168, Issue 4, 2012, Pages 344-349

  Ait Ben Haddou, E H ^a   Imounan, F ^a   Regragui, W ^a   Mouti, O ^b   Benchakroune, N ^a   Abouqal, R ^c   Benomar, A ^a,c   Yahyaoui, M ^a  

^a IBN SINA HOSPITAL   (Morocco)

^b Immeuble 61 n 10 ^*  (Morocco)

^c MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

Cerebral deep venous system thrombosis; Cyclophosphamide; Meningo encephalitis; Myelopathy; Neurobeh et disease

Indexed keywords

ANTIVITAMIN K; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BEHCET DISEASE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL EVALUATION; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HEMIPARESIS; HUMAN; MALE; MENINGOENCEPHALITIS; PARAPLEGIA; QUADRIPLEGIA; RETROSPECTIVE STUDY; SEX RATIO; SPINAL CORD DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860009331     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2011.09.006     Document Type: Article

References (15)

1. Andrews TC, D'Cruz DP, Melillo N, Sangle S, Stanford MR. Low-dose intravenous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease. Clin Rheumatol 2007;26:1365-7. (Pubitemid 47034201)
2. Araji A, Desmond KP. Neuro-Behçet's disease: epidemiology, clinical characteristics and management. Lancet Neurol 2009;8:194-204.
3. Bank I, Weart C. Dural sinus thrombosis in Behçet's disease. Arthritis Rheum 1984;27:816-8. (Pubitemid 14093731)
4. Boone RM, Kluin HC, Ramselaar CG. Thalidomide in the treatment of neuro-Behcet's syndrome. Br J Dermatol 1986;115:367-70. (Pubitemid 16055926)
5. Borhani HA. Treatment of neuro-Behçet's disease: an update. Expert Rev Neurother 2009;9:4565-74.
6. Bowirrat A, Radi S. Neuro-Behçet's disease: a report of 16 patients. Neuropsychiatr Dis Treatment 2010;6:219-25.
7. Fresco I, Siva A. Behçet's disease. Curr Treat Options Neurol 2000;2:435-48.
8. Ghayad E, Haddad ZS, Koussa S, Rassi B, Tohme. Étude de 22 observations de Neurobehçet dans une série de 170 maladies de Behçet. Presse Med 2009;38:701-9.
9. Haghighi AB, Nikseresht AR, Pourmand R. Neuro-Behçet disease: a review. Neurologist 2005;11:80-9.
10. Hamuryudan V, Ozdogan H, Yazici H. Other forms of vasculitis and pseudovasculitis. Bailliers Clin Rheumatol 1997;11: 335-55. (Pubitemid 27296601)
11. Hamuryudan V, Yazici H, Yurdakul S. Behcet's disease. Curr Opin Rheumatol 2001;13:18-22.
12. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
13. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995;38:1120-7.
14. Rodó J, Farré X, Martín E. Cyclophosphamide induced hemorrhagic cystitis: experimental study. J Urol 2001;165:2.
15. Siva A. Vasculitis of the nervous system. J Neurol 2001;248:451-68. (Pubitemid 32663879)